1,750 target contacts across 5 channels. Projected $785K/yr net revenue (most likely scenario). AI-powered outreach with ~$8,150 total setup cost.
The US ADHD supplement market has two wide-open gaps: no branded nootropic stack on Fullscript (100K+ practitioners), and zero supplement advertising in ADDitude Magazine (4M+ visitors). Brainzyme® can be the first to fill both.
Claude handles all cold outreach. It reads the database, drafts personalised emails using practitioner-specific intel, and sends via Gmail Workspace. No copywriter, no VA, no agency.
First-mover on practitioner platforms. No branded nootropic stack exists on Fullscript (100K+ practitioners) or Wellevate (50K+). Being first creates a category of one.
If it doesn't work, you've spent $8K on product seeding — which still generates brand awareness, reviews, and market intelligence even if zero partnerships convert.
The human role is relationship, not volume. One person handles warm leads only — partners who have already replied positively. Voice calls and video calls build the trust that email cannot.
The stimulant shortage created permanent behavioral shift. Since October 2022, ~15% of affected patients explored non-pharma alternatives and many didn't return. Demand is structural, not cyclical.
US market is 3–5x UK scale. These projections use conservative database sizes (1,750 contacts vs potential 6,000+). Year 2+ expansion could multiply revenue significantly.
Each finding is specific and actionable. These are not generic observations — they represent concrete opportunities that should drive outreach priority and timing.
Fullscript carries individual ingredients (bacopa, magnesium, phosphatidylserine) from Pure Encapsulations and Thorne, but no complete branded focus formula. 100,000+ practitioner accounts, protocol-driven dispensary. First branded nootropic to list creates a category of one.
The largest ADHD publication in the US is entirely pharma-dominated in its advertising. 2M+ email subscribers. Sponsored webinars available ($5–15K). No nootropic or brain supplement brand has ever advertised. The audience is actively seeking non-medication strategies.
FDA Drug Shortage Database still lists several Adderall/amphetamine dosage forms. ~15% of affected patients explored non-pharma alternatives and many didn't return to stimulants. The DEA telehealth crackdown (Schedule II requires in-person/video ID within 6 months) is pushing more patients toward non-Rx options.
Board-certified psychiatrist, author of "Finally Focused," founder of Psychiatry Redefined. Pioneer of nutritional/integrative approaches to ADHD. Runs training programs for clinicians on nutritional psychiatry. An endorsement from Dr. Greenblatt would carry extraordinary clinical authority.
Dr. Edward Hallowell is the most famous ADHD clinician in the US. 5 locations (NY, Boston, SF, Seattle, Palo Alto). Publicly pro-supplement and pro-lifestyle intervention. 10,000+ active patients. A Hallowell endorsement would be the single most powerful credibility signal in the US market.
Licensed naturopathic doctor who already creates content about nootropic supplements for ADHD management. Pre-aligned with Brainzyme®'s positioning. Her existing content means zero persuasion needed on the concept — only on the specific product.
Schedule II stimulants now require in-person or video ID verification within 6 months of initial telehealth prescription. This directly impacts telehealth ADHD companies (Done, Cerebral, ADHD Online). Patients who lose easy telehealth access to stimulants will seek alternatives. Practitioners need non-Rx options to offer.
The same AI-driven B2B outreach funnel proven in the UK (994 contacts), adapted for US regulatory language, time zones, and practitioner culture. AI handles volume; human handles relationship.
Claude drafts using database intel. References their practice, specialisms, published content.
Partner clicks through to a US-specific branded page with FDA-compliant product info and evidence.
2–3 min video from Calum or US rep: who Brainzyme is, the science, the partnership offer.
Embedded booking page (Cal.com/Calendly). 15-min video call. US time zone availability.
Starter Bundle shipped from US fulfilment point. Partner tries the product.
Wholesale account, Fullscript dispensary, or affiliate code set up. First order placed.
A convergence of stimulant shortages, DEA telehealth crackdowns, and a +123% surge in adult diagnoses has created unprecedented demand for non-pharmaceutical brain support — and no branded nootropic is serving it.
Plus an estimated 8.7 million undiagnosed. Total addressable adult ADHD population: ~24 million.
US brain health supplement market valued at $9.5–10.2 billion (2024). Nootropics segment ~$2 billion.
Nearly half of ADHD parents have tried complementary treatments including supplements. 30% of ADHD adults use supplements.
~41 million stimulant prescriptions annually. Ongoing shortage since Oct 2022 pushes patients to alternatives.
Adult ADHD diagnoses increased 123% from 2020–2024 (Epic Health Research). Women 25–44 are fastest-growing segment.
The largest practitioner dispensary in North America has zero branded nootropic stacks. First-mover advantage is wide open.
Brainzyme® occupies a unique position between mass-market brain supplements and premium practitioner-grade ingredients. No other brand combines plant-powered formulation, clinical credibility, and accessible pricing.
| Brand | Price/Mo | Segment | Practitioner Credibility |
|---|---|---|---|
| Prevagen | $40–70 | Mass-market | None |
| Neuriva | $30–50 | Mass-market | None |
| Focus Factor | $25–40 | Mass-market | None |
| Brainzyme® | $23–60 | Mid-range | 2,000+ medical professionals |
| Alpha Brain | $35–80 | Premium DTC | 1 clinical trial |
| Thesis | $79–119 | Premium DTC | None (ADHD-positioned) |
| Qualia Mind | $69–139 | Premium DTC | Minimal |
| Pure Encapsulations | Varies | Practitioner-grade | High (individual ingredients only) |
| Thorne | Varies | Practitioner-grade | High (individual ingredients only) |
Structure/function claim with required FDA disclaimer. Safe for all marketing.
Explicitly non-competing. Clinicians can recommend without conflict.
Social proof from healthcare. Substantiate with FTC-ready documentation.
Provenance and quality positioning. Differentiates from US-made mass-market.
FDA disease claim. FTC enforcement risk. Also alienates practitioners.
Positions as competition. Triggers regulatory scrutiny. Anti-medication framing alienates clinicians.
*Required disclaimer: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
Every stage of the American ADHD journey has a natural opening for brain nutrition. The key is matching the message to the moment — and being present at the touchpoints where decisions are made.
"I think I might have ADHD"
Private, telehealth, or insurance
Stimulant titration & side effects
Shortage, side effects, preference
Via practitioner, ADDitude, coach
First order via website or Fullscript
Subscription or repeat purchase
Not all channels are equal. Resource allocation should follow this priority pyramid — invest the most effort and budget in Tier 1, scale into Tier 2, experiment with Tier 3, deprioritise Tier 4.
Research-driven databases segmented by channel. Naturopathic doctor and functional medicine databases are ready; private clinic and ADHD coach databases are in development.
22 rated HIGH priority. Across 7 states (CA, WA, OR, AZ, CO, CT, MA). ADHD/neuro/nootropic specialists.
All 10 rated HIGH priority. Top IFM-certified targets. Supplement-dispensing is core to practice model.
Target: 300–500 contacts. Priority states: CA, TX, FL, NY, CO. Hallowell, Drake, Sachs flagged.
Target: 300+ contacts. PAAC-credentialed. Accessible, low gatekeeping, commercially motivated.
Note: Full database target is 500 NDs across all licensed states. Current 31 entries represent initial high-priority targets. CA, WA, OR, AZ account for ~80% of initial outreach.
Every number in this model is derived from published data sources. Per-channel purchases/month are calculated from base population × recommendation rate × purchase rate. No flat rates used.
Derived from: base patient visits/month × recommendation rate × purchase rate. Sources: APA, AANP, IFM, ICF, Fullscript TAR data. See Addendum for full methodology.
| Channel | Floor Partners | Floor Monthly | Likely Partners | Likely Monthly | Ceiling Partners | Ceiling Monthly |
|---|---|---|---|---|---|---|
| ADHD Clinics (solo) | 8 | $3,053 | 10 | $3,822 | 13 | $4,965 |
| ADHD Clinics (multi) | 4 | $3,713 | 6 | $5,569 | 7 | $6,497 |
| Naturopathic Doctors | 25 | $23,205 | 32 | $29,702 | 40 | $37,128 |
| Functional Medicine | 20 | $19,110 | 26 | $24,843 | 32 | $30,576 |
| ADHD Coaches | 24 | $852 | 30 | $1,065 | 36 | $1,277 |
| Support Groups | 6 | $328 | 8 | $437 | 11 | $601 |
| TOTAL | 87 | $50,261 | 112 | $65,438 | 139 | $80,944 |
| Item | Cost |
|---|---|
| Product samples (200 packs × ~$15 each) | ~$3,000 |
| Shipping (domestic US) | ~$1,500 |
| US FDA facility registration | ~$500 |
| US-compliant labeling redesign | ~$2,000 |
| US landing page + practitioner portal | ~$1,000 |
| Gmail Workspace for outreach | ~$150/year |
| Total Setup | ~$8,150 |
| Human resource | 1 person (warm calls only) |
| AI outreach cost | ~$0.01–0.05 per email |
Per-channel calculation: Base patient visits/month (from published surveys) × recommendation rate (% who receive supplement recommendation) × purchase rate (% who actually buy). Sources: APA Psychiatric Services (2019), AANP Membership Survey (2012), IFM Practitioner Survey (2015), ICF Global Coaching Study (2023), PMC 300,483 visits study (2014), Fullscript TAR data (2021).
Outreach conversion rates: Healthcare cold email reply rates of 5–10% (Digital Bloom 2025), adjusted upward for Brainzyme's personalised AI approach + free samples. NDs/FM: 5–8%, clinics: 3–5%, coaches: 8–12%, support groups: 4–7%.
Year 1 steady-state assumption: Partners acquired progressively over 12 months. Actual Year 1 revenue would be ~60–70% of projected due to ramp-up. Partner attrition (~10–15% annual) offset by new acquisition.
Conservative scope: Database sizes of 1,750 contacts vs potential 6,000+. Year 2+ expansion into broader ND/FM/clinic databases could multiply revenue 2–3x.
These are separate from the practitioner outreach model (which is near-zero cost). Paid opportunities require budget allocation but can accelerate reach and credibility at scale. Evaluate independently from the free sampling model.
Topic: "Nutrition and Brain Performance: What the Science Says." 2M+ email subscribers. Almost zero supplement competition. Include offer code for webinar attendees. Highest-reach ADHD media buy available.
Largest ADHD conference in the US. Professionals + consumers. First supplement brand to exhibit = strong differentiation. Evidence packs, samples, branded booth. Lead generation for practitioner and DTC channels.
3–5 podcasts simultaneously for 3-month test: ADHD reWired, ADHD Essentials, I Have ADHD, Translating ADHD, ADHD for Smart Ass Women. Host-read endorsements with promo code tracking. Expected: 1.5–3% listener conversion.
Most influential ADHD content creator. Viral TED talk. Selective — requires strong scientific backing (Brainzyme has this). One video = hundreds of thousands of views. 3–6 month lead time. High-impact if secured.
Single largest gathering of supplement-friendly practitioners in the US. Exhibitor booth + educational session. Evidence packs, product samples, practitioner pricing. Direct lead generation to Fullscript/wholesale partnerships.
Partner with 10–15 ADHD micro-influencers (50K–500K followers) for product review content. #ADHD has 35B+ views on TikTok. Higher engagement rates than macro-influencers. FTC disclosure required. Budget: $7.5–30K total.
Practitioner outreach (NDs + FM) takes 50% of effort because these channels have the highest per-partner revenue and strongest product-market fit. Clinics get 20%. Coaches and platforms make up the balance.
Highest per-partner revenue ($24–29K/yr per partner). 47–50% of patient visits result in supplement recommendations. Built-in dispensary culture. Brainzyme fits their existing workflow.
Fewer partners but high patient volume per partner. Solo clinics: 14 purchases/mo. Multi-practitioner (Hallowell type): 34 purchases/mo. Worth the higher gatekeeping effort.
Low volume per coach (1.3 purchases/mo) but highest outreach conversion rate (8–12%). Accessible, low gatekeeping. Scale via quantity. 300+ targets.
Fullscript (100K+), Wellevate (50K+), Natural Partners (30K+). One-time application effort, ongoing passive distribution. Multiplies all practitioner outreach.
200+ CHADD chapters. Sampling model (~$200–500/chapter). Low revenue per group but builds grassroots awareness and peer-to-peer word of mouth.
Each audience type requires different language, tone, and emphasis. All messaging is FDA structure/function claim compliant. Never use disease claims.
Key hooks: Fullscript-compatible dispensary model, 30% wholesale margin, free Starter Bundle to evaluate, ready-made patient protocol template.
Key hooks: Pre-formulated alternative to individual ingredient stacking, protocol-ready, saves consultation time on supplement recommendations.
Key hooks: Patients already asking about supplements, gives clinicians a vetted answer. Wholesale pricing. No prescribing conflict.
Key hooks: Free product to try, affiliate commission, client welcome pack option, no prescribing boundaries to navigate.
The same infrastructure proven in the UK (994 contacts), adapted for US time zones, regulatory language, and healthcare email guidelines. Maximum 50 emails per day per account.
CSV with practice intel
Personalised per contact
≤50/day per account
AI triages responses
Human takes over
Phase 1 establishes US market infrastructure. Phase 2 launches practitioner outreach at scale. Phase 3 expands into paid opportunities and secondary channels.
Complete FDA facility registration + US agent designation. Redesign labeling for US Supplement Facts panel. Submit Fullscript brand application with GMP/HACCP certificates. Set up US Gmail Workspace (warmup period). Build US-specific partner landing page with FDA-compliant copy. Establish US fulfilment arrangement for sample packs.
Wave 1 (Month 2–3): ND outreach — CA, WA, OR, AZ. 500 contacts. Free sample packs for top 100.
Wave 2 (Month 3–4): FM practitioners — IFM directory. 400 contacts. Protocol template development.
Wave 3 (Month 4–5): Private ADHD clinics — priority states. 400 contacts. Hallowell/Drake flagship outreach.
Wave 4 (Month 5–6): ADHD coaches — PAAC directory. 300 contacts. Affiliate commission model.
Sample distribution throughout. Human follows up on warm leads from each wave.
Scale active partnerships with reorder support. Apply to Wellevate and Natural Partners. Evaluate ADDitude Magazine sponsored webinar ($5–15K). Explore CHADD conference exhibition for following year. Launch podcast sponsorship test (3–5 shows). Begin CHADD chapter-level sponsorships in priority metros. Assess Jessica McCabe partnership feasibility. Expand databases to 6,000+ contacts for Year 2.
Before launching any US partnerships, Brainzyme must complete these regulatory steps. Most are straightforward administrative processes, not barriers.
All channels plotted on a 2×2 grid: effort required vs expected impact. Focus on the upper-left quadrant — low effort, high impact.
Fullscript listing
ND bulk outreach
IFM practitioners
ADHD coaches (PAAC)
AI outreach funnel
ADDitude Magazine
Hallowell partnership
Jessica McCabe
US clinical trial
CHADD national
Telehealth providers
State ND conferences
CHADD chapter sponsorship
ADDA events
Podcast sponsorship
Women's ADHD events
Hospital ADHD programs
Corporate wellness
Mass retail (Walmart)
Amen Clinics deal
Reddit (prohibited)
Everything in this report is dependent on these three foundational decisions. No outreach can begin until they are actioned.
Register Better Nutritional Science Ltd with the FDA as a foreign supplement manufacturer. Designate a US agent. Online process, ~$500, takes 2–4 weeks. This is the single prerequisite for all US sales — Fullscript listing, wholesale partnerships, and DTC all require it. No regulatory risk; it is a registration, not an approval.
Create a dedicated Gmail Workspace account (e.g., [email protected]) with SPF/DKIM/DMARC authentication. ~$150/year. 2-week warmup period before volume sending. This is the infrastructure that powers the AI outreach pipeline — Claude drafts and sends all emails through this account.
Submit brand application to Fullscript with GMP/HACCP certificates, Certificates of Analysis, and product documentation. Requires FDA registration first. Application review takes 4–8 weeks. If accepted, Brainzyme becomes the first branded nootropic stack on a platform used by 100,000+ practitioners. This is a first-mover opportunity with no current competition.